The selective FXR agonist INT-747 modulated lipid accumulation, perhaps by inhibiting NF-κB transcriptional activity, and improved proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis in a streptozotocin-induced diabetic nephropathy mouse model (3). Here, NFKB1 is linked to diabetic kidney disease.